Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS) Fosmanogepix 1000mg IV (loading dose) and 600mg IV or 800mg oral (maintenance dose) was associated with an all-cause mortality of 25% at Day 42 with accept

🦠 New study in Clinical Infectious Diseases: Fosmanogepix shows potential for treating invasive mold infections by Aspergillus & rare molds in high-risk patients with limited options.
📄 Read more: doi.org/10.1093/cid/...
#InfectiousDiseases #Antifungals #FMGX